health canada semaglutide Approves Ozempic® (semaglutide injection) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) in Adults with Type 2 Diabetes Health Canada authorizes Dr. Reddy's

Our licensed providers deliver the professional oversight and personalized support you need to achieve real, lasting results with confidence

These are individuals who could be a fit for a GLP-1 medication: Individuals with type 2 diabetes who struggle to manage blood sugar levels with other treatments

While GLP-1 medications show promise and may offer benefits, it's crucial to weigh the potential risks and have an in-depth discussion with your healthcare team

Baseline screening through PlexusDx helps identify your specific risk areas, making targeted supplementation both evidence-based and personalized

2022;45(Supplement_1):S12543

On the other hand, Wegovys warnings include acute pancreatitis, gallbladder disease, acute kidney injury, diabetic retinopathy complications, and increased heart rate